PET-CT

Diagnostic Imaging Services Market Size to Reach USD 67.94 Billion in 2030 | Emergen Research

Retrieved on: 
Monday, January 23, 2023
Safety, Merative, USD, Radiological Society of North America, Hospital, IBM, FDA, ASC, Radiology, MRI, Conditional sentence, Degenerative disc disease, Angiography, Sodium, Ultrasound, Death, Fatality, Surgeon, General Electric Company, Patient, Acquisition, Radiation exposure, Agfa-Gevaert, Communication, Vertebral compression fracture, Radiation, NCD, Vegetable, Annual general meeting, Prevalence, CT, Ionization, Shimadzu, Magnetic resonance imaging, Developed country, Diagnosis, Carestream Health, PET-CT, Non-communicable disease, Tobacco, CT scan, IBM Watson, Risk, Growth, World Health Organization, Google Images, RSNA, Neoplasm, Medical imaging

VANCOUVER, BC, Jan. 23, 2023 /PRNewswire/ -- The diagnostic imaging services market size reached USD 40.80 Billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, BC, Jan. 23, 2023 /PRNewswire/ -- The diagnostic imaging services market size reached USD 40.80 Billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period, according to latest analysis by Emergen Research .
  • Rising prevalence of chronic diseases, increasing elderly population, and rapid technological advancements in the healthcare diagnostic industry are some of the key factors boosting revenue growth of diagnostic imaging services market.
  • In addition, several product launches by key market players in diagnostic field are driving the growth of this market globally.
  • The diagnostic imaging services market is expected to register a CAGR of 5.8% over the forecast period and revenue is projected to increase from USD 40.80 in 2021 to USD 67.94 Billion in 2030.

Diagnostic Imaging Services Market Size to Reach USD 67.94 Billion in 2030 | Emergen Research

Retrieved on: 
Monday, January 23, 2023
Safety, Merative, USD, Radiological Society of North America, Hospital, IBM, FDA, ASC, Radiology, MRI, Conditional sentence, Degenerative disc disease, Angiography, Sodium, Ultrasound, Death, Fatality, Surgeon, General Electric Company, Patient, Acquisition, Radiation exposure, Agfa-Gevaert, Communication, Vertebral compression fracture, Radiation, NCD, Vegetable, Annual general meeting, Prevalence, CT, Ionization, Shimadzu, Magnetic resonance imaging, Developed country, Diagnosis, Carestream Health, PET-CT, Non-communicable disease, Tobacco, CT scan, IBM Watson, Risk, Growth, World Health Organization, Google Images, RSNA, Neoplasm, Medical imaging

VANCOUVER, BC, Jan. 23, 2023 /PRNewswire/ -- The diagnostic imaging services market size reached USD 40.80 Billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, BC, Jan. 23, 2023 /PRNewswire/ -- The diagnostic imaging services market size reached USD 40.80 Billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period, according to latest analysis by Emergen Research .
  • Rising prevalence of chronic diseases, increasing elderly population, and rapid technological advancements in the healthcare diagnostic industry are some of the key factors boosting revenue growth of diagnostic imaging services market.
  • In addition, several product launches by key market players in diagnostic field are driving the growth of this market globally.
  • The diagnostic imaging services market is expected to register a CAGR of 5.8% over the forecast period and revenue is projected to increase from USD 40.80 in 2021 to USD 67.94 Billion in 2030.

Micronoma Receives FDA Breakthrough Device Designation for OncobiotaLUNG, A Novel Liquid Biopsy Assay for Lung Carcinoma Detection

Retrieved on: 
Tuesday, January 10, 2023
Research, Medical Devices, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Disease, American Cancer Society, Survival rate, Trust, Prostate cancer screening, Lung cancer, Colon, Breast, Malignancy, FDA, CT, Manuscript, Food, Nature, Breakthrough, Cancer, Natural killer cell enteropathy, Clinical trial, Science, Cell, Food and Drug Administration Amendments Act of 2007, PET-CT, Health, Medical device, Medical imaging

Micronoma , the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA).

Key Points: 
  • Micronoma , the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA).
  • As a result, Micronoma can expect continued guidance and prioritized reviews from the agency of its upcoming clinical trial and concomitant pre-market approval processes.
  • Early detection of lung cancer can lead to a higher survival rate.
  • “Receiving FDA Breakthrough Device Designation is a fantastic recognition by the agency and a great milestone for Micronoma,” said Sandrine Miller-Montgomery, Micronoma CEO and co-founder.

HospeTrack Hospital Intelligence for Denmark: A Vision of Modernizing Hospital Infrastructure for a Sustainable Future - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 17, 2022
Hospitals, Health Technology, Health, Hospital, EUR, PET-CT, Health information management, Information technology, SPECT, Cath lab, Data, EMR, Medicine, Database, Renewable energy, Medical imaging

Denmark's healthcare market to be driven by the country's vision of modernizing hospital infrastructure for a sustainable future.

Key Points: 
  • Denmark's healthcare market to be driven by the country's vision of modernizing hospital infrastructure for a sustainable future.
  • As of 2021-22, Denmark has about 56 public and 58 private healthcare facilities including imaging centers spread throughout the five regions.
  • This HospeTrack is the largest database of hospital level medical equipment installed base data, currently available on the market.
  • The Denmark Total Hospital & Medical IB Mapping report was updated in 2022 and includes over 114 hospitals and imaging centers from the country with their health infrastructure detailed out.

SeekIn Demonstrates the Power of Treatment Response Monitoring Test at the Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo

Retrieved on: 
Monday, November 7, 2022
Neoplasm, DNA, Research, Kerri Seekins-Crowe, Time, Recurrence, CNA, FS, Acute leukemia, MTB, Radiation, PET-CT, WHO, MRD, Quality of life, PFS, Artificial intelligence, CEO, AMP, Cancer, Technology, Circulating tumor DNA, Survival, Diagnosis, Leukemia, Patient, Progression-free survival, Blood, Medical imaging, Medical device

SHENZHEN, China, Nov. 7, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced the results of the pan-cancer/pan-indication treatment response monitoring test, SeekInClarity®, which were presented at the AMP 2022 Annual Meeting & Expo in Phoenix, Arizona, United States.

Key Points: 
  • SeekInClarity is a CE-IVD Mark, cost-effective, blood-based pan-cancer/pan-indication treatment response monitoring test that does not require cancer tissue analysis.
  • SHENZHEN, China, Nov. 7, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced the results of the pan-cancer/pan-indication treatment response monitoring test, SeekInClarity, which were presented at the AMP 2022 Annual Meeting & Expo in Phoenix, Arizona, United States.
  • Imaging analysis is often used to assess disease burden and to evaluate treatment response for cancer patients.
  • In order to improve upon our current ability to monitor cancer treatment response, the development of novel response assessment techniques is necessary.

Global Oropharyngeal Cancer Diagnosis and Therapeutics Market Report 2022-2028: Featuring AB Sciences, GE Healthcare, Boston Biomedical, Merck, Novartis - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Health, Oncology, Awareness, Therapy, Growth, Hospital, CAGR, Radiation, Scan (company), PET-CT, Biopsy, High, Oropharyngeal cancer, Diagnosis, CT, MRI, Endoscopy, Scan, Patient, Cancer, Medical device, Medical imaging

The global oropharyngeal cancer diagnosis and therapeutics market are anticipated to grow at a substantial CAGR of 4.5% during the forecast period.

Key Points: 
  • The global oropharyngeal cancer diagnosis and therapeutics market are anticipated to grow at a substantial CAGR of 4.5% during the forecast period.
  • The global oropharyngeal cancer diagnosis and therapeutics market are segmented based on the diagnostic type, treatment type, and end-users.
  • Geographically the global oropharyngeal cancer diagnosis and therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
  • Global Oropharyngeal Cancer Diagnosis and Therapeutics Market Research and Analysis by Treatment Type.

Nashville Biosciences Adds Medical Imaging to Clinical Phenotype Resources

Retrieved on: 
Monday, October 24, 2022
Machine learning, Vanderbilt University Medical Center, Phenotype, Research, MRI, Artificial intelligence, Transesophageal echocardiogram, CT, CEO, PET-CT, Medical Center, EMR, Roger Hawkins (drummer), VUMC, Biomarker, Mammography, Medical imaging

De-identified medical images and corresponding radiologic reports can now be used by Nashville Biosciences to develop deeper, more complex clinical phenotypes and in subsequent analyses of the resulting cohorts.

Key Points: 
  • De-identified medical images and corresponding radiologic reports can now be used by Nashville Biosciences to develop deeper, more complex clinical phenotypes and in subsequent analyses of the resulting cohorts.
  • Medical imaging is commonly used in the clinical setting to diagnose and monitor a wide range of health disorders.
  • When asked about adding medical images to Nashville Biosciences' resources, CEO and co-founder Leeland Ekstrom stated, "One of the strengths we bring to our clients' R&D efforts is the depth of clinical phenotype data from VUMC's EMR.
  • Nashville Biosciences, a wholly-owned Vanderbilt University Medical Center (VUMC) subsidiary, was created to harness the Medical Center's extensive genomic and bioinformatics resources for drug and diagnostics discovery and development.

Nashville Biosciences Adds Medical Imaging to Clinical Phenotype Resources

Retrieved on: 
Monday, October 24, 2022
Machine learning, Vanderbilt University Medical Center, Phenotype, Research, MRI, Artificial intelligence, Transesophageal echocardiogram, CT, CEO, PET-CT, Medical Center, EMR, Roger Hawkins (drummer), VUMC, Biomarker, Mammography, Medical imaging

De-identified medical images and corresponding radiologic reports can now be used by Nashville Biosciences to develop deeper, more complex clinical phenotypes and in subsequent analyses of the resulting cohorts.

Key Points: 
  • De-identified medical images and corresponding radiologic reports can now be used by Nashville Biosciences to develop deeper, more complex clinical phenotypes and in subsequent analyses of the resulting cohorts.
  • Medical imaging is commonly used in the clinical setting to diagnose and monitor a wide range of health disorders.
  • When asked about adding medical images to Nashville Biosciences' resources, CEO and co-founder Leeland Ekstrom stated, "One of the strengths we bring to our clients' R&D efforts is the depth of clinical phenotype data from VUMC's EMR.
  • Nashville Biosciences, a wholly-owned Vanderbilt University Medical Center (VUMC) subsidiary, was created to harness the Medical Center's extensive genomic and bioinformatics resources for drug and diagnostics discovery and development.

United Imaging Healthcare Attends European Association of Nuclear Medicine Congress With uEXPLORER®, The World's First Total-Body PET/CT

Retrieved on: 
Monday, October 24, 2022
Congress, Yale University, UIH, FOV, Nuclear medicine, Neurological disorder, PET-CT, Cardiology, IPO, NX, European Association of Nuclear Medicine, EANM, Lists of diseases, Technology, Molecular imaging, Marketing, Industry, Association, Umi, UC, Alzheimer's disease, PET/CT, Health, CEO, University of California, Davis, Neurodegeneration, PET, Degenerative disease, CTO, Solution, Medical imaging

BARCELONA, Spain, Oct. 24, 2022 /PRNewswire/ --United Imaging Healthcare (UIH), a global innovator in advanced medical imaging, debuts at the European Association of Nuclear Medicine (EANM) Congress recently in Barcelona with its groundbreaking PET/CT, uEXPLORER.

Key Points: 
  • BARCELONA, Spain, Oct. 24, 2022 /PRNewswire/ --United Imaging Healthcare (UIH), a global innovator in advanced medical imaging, debuts at the European Association of Nuclear Medicine (EANM) Congress recently in Barcelona with its groundbreaking PET/CT, uEXPLORER.
  • The system offers total-body dynamic scanning, allows ultra-low patient dose, and produces ultra-high image resolution, changing how whole-body PET/CT imaging has traditionally been performed.
  • Fresh off the heels of its IPO, the company hit another landmark, shipping its 20,000th global installation recently.
  • Now UIH has a well-equipped local team including marketing, training, and after-sales service in Europe.

Arizona Oncology Cancer Center working with NexCore Group on new cancer treatment center

Retrieved on: 
Thursday, October 6, 2022
Physician, Caregiver, HDR, Radiation oncologist, Healthcare Facilities Accreditation Program, Disease, Radiation, LINAC, Patient, Hospital, Hematology-Oncology and Stem Cell Transplantation Research Center, Urology, Modern Healthcare, Cancer, CT, Google Images, Radiation therapy, Real estate development, Breast cancer, Nutritionist, Oncology, Pharmacist, Surgical oncology, FDA, PET-CT, Medical imaging, Medicine, Hematology, Research, Medicine

DENVER, Oct. 6, 2022 /PRNewswire/ -- This past weekend, national health care, life sciences and senior housing real estate developer NexCore Group, in collaboration with Arizona Oncology, broke ground on a state-of-the-art cancer treatment center in Prescott, Ariz. located at 5430 Landmark Lane. Arizona Oncology, one of the largest medical groups in Arizona devoted exclusively to cancer care, and NexCore will develop a new 22,105-square-foot facility anticipated to open in September 2023. Once operational, the Arizona Oncology Cancer Center will offer patients in the region convenient access to the latest cancer treatment services and technologies.

Key Points: 
  • Once operational, the Arizona Oncology Cancer Center will offer patients in the region convenient access to the latest cancer treatment services and technologies.
  • The Arizona Oncology Cancer Center is currently located at 3188 N. Windsong Dr. but will relocate once this project is complete.
  • "Arizona Oncology is committed to evolving our practices to best fit the needs of our patients," said Iyad Hamarneh, medical oncologist with Arizona Oncology.
  • When completed, our cancer center will be the only practice in the quad-city region that will offer medical oncology, radiation oncology and hematology services for our community."